Mineralys Therapeutics
Mineralys Therapeutics is a fully remote, clinical-stage biopharmaceutical company focused on developing medicines for hypertension, chronic kidney disease, sleep apnea, and other diseases related to dysregulated aldosterone. The company is preparing for its first product launch and is seeking a senior leader to oversee pricing and contracting strategies.
Headquarters
Radnor, Pennsylvania, United States
Company Size
11-50 employees
Founded
2020
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on improving outcomes for people with hypertension, chronic kidney disease (CKD), and cardio-renal-metabolic diseases driven by dysregulated aldosterone. The company's lead investigational candidate, Lorundrostat, is designed to target the underlying role of aldosterone in these conditions. Mineralys is advancing its pipeline through clinical development with the goal of delivering better outcomes for patients inadequately served by current therapies.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Mineralys Therapeutics.
90% above the average for this role
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Insight
3 days ago
Senior Director, Pricing & Contracting
Definium Therapeutics
Director, Pricing & Contracting
iSi Environmental
Director, Pricing & Contracting
Intellia Therapeutics
Senior Director, Pricing & Contracting
Zenas BioPharma
Executive Director, U.S. Pricing & Contracting
Servier
Executive Director Pricing & Contracting
Novartis